Nektar Rises on Opioid Trial: San Francisco Mover
This article is for subscribers only.
Nektar Therapeutics rose the most in 11 months after a study of its new slow-release painkiller showed it may not lead to abuse of the drug.
Nektar rose 12 percent to $10.95 at the close in New York, its largest single-day increase since July 16. The San Francisco-based company gained 36 percent in the past 12 months.